BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jablonski R, Bhorade S, Strek ME, Dematte J. Recognition and Management of Myositis-Associated Rapidly Progressive Interstitial Lung Disease. Chest 2020;158:252-63. [PMID: 32059958 DOI: 10.1016/j.chest.2020.01.033] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Rubin J, Hallowell RW, Witkin AS, Shelton K, Raz Y. Response. Chest 2021;160:e681-2. [PMID: 34872691 DOI: 10.1016/j.chest.2021.08.048] [Reference Citation Analysis]
2 Cassone G, Sebastiani M, Vacchi C, Erre GL, Salvarani C, Manfredi A. Efficacy and safety of mycophenolate mofetil in the treatment of rheumatic disease-related interstitial lung disease: a narrative review. Drugs Context 2021;10:2020-8-8. [PMID: 33505480 DOI: 10.7573/dic.2020-8-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Laporte A, Mariampillai K, Allenbach Y, Pasi N, Donciu V, Toledano D, Granger B, Benveniste O, Grenier PA, Boussouar S. Idiopathic inflammatory myopathies: CT characteristics of interstitial lung disease and their association(s) with myositis-specific autoantibodies. Eur Radiol 2022. [PMID: 35022809 DOI: 10.1007/s00330-021-08411-w] [Reference Citation Analysis]
4 Liang J, Cao H, Liu Y, Ye B, Sun Y, Ke Y, He Y, Xu B, Lin J. The lungs were on fire: a pilot study of 18F-FDG PET/CT in idiopathic-inflammatory-myopathy-related interstitial lung disease. Arthritis Res Ther 2021;23:198. [PMID: 34301306 DOI: 10.1186/s13075-021-02578-9] [Reference Citation Analysis]
5 Mehta AA, Paul T, Cb M, Haridas N. Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease: report of two cases. BMJ Case Rep 2021;14:e240046. [PMID: 33910791 DOI: 10.1136/bcr-2020-240046] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Qin X, Chen X, Deng Y, Gu YY, Zeng L, Huang S, Sun L, Li S. A 12-Year-Old Girl Presenting With Recurrent Dyspnea and Pulmonary Ground-Glass Opacities. Chest 2021;160:e45-50. [PMID: 34246388 DOI: 10.1016/j.chest.2021.02.002] [Reference Citation Analysis]
7 Li Y, Li Y, Wu J, Miao M, Gao X, Cai W, Shao M, Zhang X, Xu Y, Cong L, He J, Sun X. Predictors of Poor Outcome of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease in a Chinese Cohort with Dermatomyositis. J Immunol Res 2020;2020:2024869. [PMID: 33299896 DOI: 10.1155/2020/2024869] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Liang J, Cao H, Yang Y, Ke Y, Yu Y, Sun C, Yue L, Lin J. Efficacy and Tolerability of Nintedanib in Idiopathic-Inflammatory-Myopathy-Related Interstitial Lung Disease: A Pilot Study. Front Med (Lausanne) 2021;8:626953. [PMID: 33614683 DOI: 10.3389/fmed.2021.626953] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Yu X, Gu S, Li M, Zhan Q. Awake Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome: Which Clinical Issues Should Be Taken Into Consideration. Front Med (Lausanne) 2021;8:682526. [PMID: 34277659 DOI: 10.3389/fmed.2021.682526] [Reference Citation Analysis]
10 Gono T, Okazaki Y, Kuwana M. Antiviral proinflammatory phenotype of monocytes in anti-MDA5 antibody-associated interstitial lung disease. Rheumatology (Oxford) 2021:keab371. [PMID: 33890985 DOI: 10.1093/rheumatology/keab371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Li Y, Gao X, Li Y, Jia X, Zhang X, Xu Y, Gan Y, Li S, Chen R, He J, Sun X. Predictors and Mortality of Rapidly Progressive Interstitial Lung Disease in Patients With Idiopathic Inflammatory Myopathy: A Series of 474 Patients. Front Med (Lausanne) 2020;7:363. [PMID: 32850886 DOI: 10.3389/fmed.2020.00363] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
12 Dunga SK, Kavadichanda C, Gupta L, Naveen R, Agarwal V, Negi VS. Disease characteristics and clinical outcomes of adults and children with anti-MDA-5 antibody-associated myositis: a prospective observational bicentric study. Rheumatol Int 2021. [PMID: 34050793 DOI: 10.1007/s00296-021-04897-1] [Reference Citation Analysis]
13 Yan W, Wang L, Chen Z, Gu C, Chen C, Liu X, Ye Q. Knockdown of lncRNA HAGLR promotes Treg cell differentiation through increasing the RUNX3 level in dermatomyositis. J Mol Histol. [DOI: 10.1007/s10735-021-10051-9] [Reference Citation Analysis]
14 Wang Q, Gao C, Zhang C, Yao M, Liang W, Sun W, Zheng Z. Tumor markers are associated with rapidly progressive interstitial lung disease in adult-dermatomyositis. Clin Rheumatol 2022. [PMID: 35138465 DOI: 10.1007/s10067-022-06089-z] [Reference Citation Analysis]
15 Panagopoulos P, Goules A, Hoffmann-Vold AM, Matteson EL, Tzioufas A. Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis 2021;13:1759720X211037519. [PMID: 34471427 DOI: 10.1177/1759720X211037519] [Reference Citation Analysis]